id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2026-D-1256-0002,FDA,FDA-2026-D-1256,Considerations for the use of the Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic Conditions with Known Biological Cause; Draft Guidance for Industry,Other,Guidance,2026-02-25T05:00:00Z,2026,2,2026-02-25T05:00:00Z,2026-04-28T03:59:59Z,2026-03-02T10:00:22Z,,1,0,09000064b91daa48
FDA-2026-D-1256-0001,FDA,FDA-2026-D-1256,Considerations for the Use of the Plausible Mechanism Framework To Develop Individualized Therapies That Target Specific Genetic Conditions With Known Biological Cause; Draft Guidance for Industry; Availability,Notice,Notice of Availability,2026-02-25T05:00:00Z,2026,2,2026-02-25T05:00:00Z,,2026-02-25T19:04:38Z,2026-03713,0,0,09000064b91da53f